Pemafibrate (Parmodia®): First Global Approval – second (PPAR)-α agonist joins Japanese market in a bid to tip the lipoprotein cholesterol balance

Pemafibrate (Parmodia®): First Global Approval –  second (PPAR)-α agonist joins Japanese market in a bid to tip the lipoprotein cholesterol balance

The recent first global approval of pemafibrate has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Pemafibrate (Parmodia®): First Global Approval – second (PPAR)-α agonist joins Japanese market in a bid to tip the lipoprotein cholesterol balance”